Bioenvision News (NASDAQ:BIVN)
| Latest Bioenvision News Headlines | | Date | Time | Source | | | 10/23/2007 | 5:40PM | PRNUS | HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index
NEW YORK, Oct. 23 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the calculating agent for the HealthShares(TM) Indexes, that effective at the opening of trading on Friday, October 26, 2007, Immunogen... More...>> |
| 10/22/2007 | 4:50PM | PRNUS | Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
CAMBRIDGE, Mass., and NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and Bioenvision, Inc. (NASDAQ:BIVN) announced this afternoon that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. The... More...>> |
| 10/10/2007 | 2:57PM | PRNUS | Delaware Court Approves Bioenvision, Genzyme Joint Petition
Special Meeting to be Reconvened on October 22
NEW YORK and CAMBRIDGE, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Bioenvision, Inc. (NASDAQ:BIVN) and Genzyme Corporation (NASDAQ:GENZ) announced today that the Court of Chancery of the State of Delaware granted a petition filed yesterday by both companies to reconvene Bioenvision's... More...>> |
| 09/27/2007 | 8:45AM | PRNUS | Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
CAMBRIDGE, Mass., Sept. 27 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) confirmed today that it will not change its purchase price for Bioenvision (NASDAQ:BIVN) at $5.60 in cash per outstanding common share as set forth in the merger agreement between the two companies. Genzyme already owns approximately... More...>> |
| 09/06/2007 | 9:49AM | PRNUS | Elliott 'Extremely Dissatisfied' With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
Major Shareholder Will NOT Vote for Merger; Says 'Shareholders Have Already Spoken' by Rejecting Tender Offer at $5.60 per Share
NEW YORK, Sept. 6 /PRNewswire-FirstCall/ -- Elliott Associates, L.P. (together with funds under common management), a major shareholder of Bioenvision (NASDAQ:BIVN), today said the following... More...>> |
| 07/27/2007 | 6:24PM | PRNUS | Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Bioenvision, Inc.
OKLAHOMA CITY, July 27 /PRNewswire/ -- On July 13, 2007, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Bioenvision, Inc. (NASDAQ:BIVN). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange... More...>> |
| 07/10/2007 | 9:27AM | PRNUS | Genzyme Completes Tender Offer to Acquire Bioenvision, Inc.
Proxy Statement to Be Prepared for Shareholder Meeting on Merger
CAMBRIDGE, Mass., July 10 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it has completed its tender offer to acquire shares of Bioenvision, Inc. (NASDAQ:BIVN) capital stock and that a proxy statement will now be prepared... More...>> |
| 07/02/2007 | 9:45AM | PRNUS | Genzyme Extends Tender Offer to Acquire Bioenvision, Inc.
Waives Minimum Tender Condition; 100 Percent of Preferred Shares Now Tendered
CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it is waiving the condition to its tender offer that it acquire at least 50 percent of the outstanding shares of common stock of Bioenvision... More...>> |
| 06/27/2007 | 12:30PM | PRNUS | Genzyme Corporation Moves Closer to Acquiring Bioenvision, Inc.
Request for Preliminary Injunction to Prevent Transaction is Withdrawn
CAMBRIDGE, Mass., June 27 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that a motion for a preliminary injunction to delay its proposed acquisition of Bioenvision, Inc. (NASDAQ:BIVN) has been withdrawn in the Delaware... More...>> |
| 05/29/2007 | 9:09AM | PRNUS | Genzyme Corporation to Acquire Bioenvision, Inc.
To Gain Exclusive, Worldwide Rights to Clofarabine
CAMBRIDGE, Mass. and NEW YORK, May 29 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and Bioenvision, Inc. (NASDAQ:BIVN) announced today that they have reached an agreement under which Genzyme will acquire Bioenvision in an all cash transaction valued at... More...>> |
| 03/15/2005 | 11:47AM | PRNUS | SAP Business One and CompuData Selected by Bioenvision
SAP Business One and CompuData Selected by Bioenvision
PHILADELPHIA, March 15 /PRNewswire/ -- CompuData, an SAP Business Partner,
today announced that it has been selected by biopharmaceutical company
Bioenvision, Inc. (NASDAQ:BIVN) to implement SAP(R) Business One, SAP's
integrated business management software solution... More...>> |
| 12/21/2004 | 8:05AM | PRNUS | Genzyme Completes Acquisition of ILEX Oncology, Inc.
Genzyme Completes Acquisition of ILEX Oncology, Inc.
Positions Itself in Expanding Oncology Market
CAMBRIDGE, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Genzyme Corporation
(NASDAQ:GENZ) announced today that it has completed its acquisition of ILEX
Oncology, Inc., a cancer drug development company with a growing marketed
product... More...>> |
| 11/12/2004 | 6:30PM | PRNUS | Semi-Annual Changes to the NASDAQ Biotechnology Index
Semi-Annual Changes to the NASDAQ Biotechnology Index
NEW YORK, Nov. 12 /PRNewswire/ -- The Nasdaq Stock Market, Inc. (NASDAQ(R))
(OTC:NDAQ) (BULLETIN BOARD: NDAQ) announced today the results of the
semi-annual re-ranking of the NASDAQ Biotechnology Index(R) (NASDAQ:NBI), which
will become effective with the market... More...>> |
|
|
|